Table 4 Disease activity, damage indices, hormonal assessment, ultrasound evaluation, and treatment lines in relation to menstrual cycle among cases

Disease duration (years)

2.5 (0.2-5)

2 (1–5)

5.5 (2–8)

3 (1–10)

5.5 (5.5–5.5)

6 (4–7)

Age of menarche

13 (0–15)

12 (11–13)

13 (11–14)

12 (11–14)

0 (0–0)

12 (11–13)

Age of puberty onset

13 (0–15) $

12 (11–13) $

13 (11–14)

12 (11–14)

0 (0–0)

12 (11–13)

Disease activity and damage indices

Activity index/MYOACT

7 (4–25)

6 (2–20)

1 (0–2)

4 (0–33)

30 (30–30)

8 (0–12)

Damage index/MITAX

2 (0–4) $

0 (0–2) $

4 (4–4)

2 (1-2.5)

30 (30–30)

4 (0–7)

Hormonal assessment

Estradiol (pg/mL)

28.1

(11.5–30.5)

28.7

(20.2–43.2)

30.0

(8.3–40.4)

27.6

(22.6–42.4)

19.9

(19.9–19.9)

23.7

(20.4–28.5)

Follicular stimulating hormone (mIU/L)

4.4

(2.8–8.3)

5.6

(3.8–9.3)

5.4

(2-8.3)

5.8

(2.7–8.2)

0.8

(0.8–0.8)

4.8

(3.5–8.5)

Luteinizing hormone (mIU/L)

4.5

(0.8–14.7)

5.3

(1.5–17)

3.1

(0.2–5.9)

5.0

(1.4–15)

0.1

(0.1–0.1)

4.5

(3-7.7)

Prolactin (ng/mL)

12.7

(1.5–20)

17.0

(5–22)

20.6

(13.3–29)

14.3

(1.6–27.4)

5.5

(5.5–5.5)

11

(4.8–22.8)

U/S evaluation

Right ovarian volumes (cm3)

9 (4–11)

8 (6–11)

6 (6–11)

7 (5–11)

4 (4–4)

7 (5–7)

Left ovarian volumes (cm3)

6 (4–13)

7 (6–12)

9 (6–11)

6 (5–12)

4 (4–4)

7 (5–7)

Diameter of the endometrium (cm)

7 (4–11)

6 (6–11)

8 (6–12)

6 (5–11)

4 (4–4)

6 (6–6)

Cumulative dose of steroid (gm) *@

6

(3.6–30) $

4.3

(0.2–14) $

0.5

(0-3.6)

0.5

(0–10)

20.8

(20.8–20.8)

0.05

(0.02 to 3.6)

Other treatment lines N (%)

10 (100.0)

11 (100.0)

4 (100.0)

19 (100.0)

1 (100.0)

6 (85.7)

Cyclophosphamide use N (%)

4 (40)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Cumulative dose of cyclophosphamide (gm)

6 (6–6)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)